irschlin
pyrimidin
base
occur
high
frequenc
fig
therefor
low
concentr
nucleic
acid
eg
pathogen
low
titer
specif
react
even
presenc
larg
amount
biolog
materi
theoret
format
one
crosslink
strand
nucleic
acid
suffici
prevent
replic
genom
frequenc
interact
amotosalen
molecul
pyrimdin
occur
ie
coval
bond
form
determin
differ
nucleic
acid
organ
averag
crosslink
form
everi
base
pair
reaction
nucleic
acid
depend
gener
activ
oxygen
speci
known
caus
damag
cell
effect
even
absenc
oxygen
high
frequenc
interact
make
replic
also
transcript
gene
imposs
inhibit
dna
repair
mechan
amotosalen
sequenc
specif
thu
effici
inactiv
broad
spectrum
pathogen
addit
amotosalennucl
acid
crosslink
occur
presenc
uva
light
absenc
featur
repres
anoth
uniqu
safeti
measur
reaction
tightli
control
ex
vivo
simpli
turn
light
sourc
intercept
technolog
pathogen
inactiv
platelet
plasma
compon
base
two
major
step
mix
blood
compon
amotosalen
final
concentr
suspens
illumin
uva
light
jcm
thereaft
residu
amotosalen
free
photoproduct
adsorb
compound
adsorpt
devic
cad
illumin
devic
specif
design
allow
uva
light
illumin
blood
compon
report
light
shorter
wavelength
like
uvb
uvc
detriment
effect
platelet
protein
gener
activ
oxygen
speci
therefor
exposur
uvb
uvc
light
complet
prevent
intercept
process
entir
procedur
perform
close
integr
dispos
set
figur
show
intercept
illumin
devic
integr
dispos
set
platelet
plasma
platelet
plasma
product
attach
via
one
steril
connect
dispos
set
pass
pouch
contain
amotosalen
illumin
contain
set
place
illumin
uva
light
illumin
perform
min
two
product
illumin
parallel
illumin
suspens
transfer
contain
cad
depend
product
workflow
blood
bank
adsorpt
perform
min
plasma
flowthrough
h
pend
work
flow
orbit
shaker
platelet
subsequ
platelet
plasma
transfer
transmiss
pathogen
via
blood
transfus
still
major
threat
expert
confer
establish
need
proactiv
approach
conclud
introduct
pathogen
inactivationreduct
technolog
requir
thorough
safeti
profil
comprehens
preclin
clinic
develop
ongo
hemovigil
program
intercept
blood
system
pathogen
inactiv
util
amotosalen
synthet
psoralen
formerli
activ
compound
uva
light
psoralen
like
trimethylpsoralen
tmp
natur
occur
photoact
substanc
found
number
plant
lime
celeri
parsnip
plant
recogn
hundr
year
benefici
effect
certain
skin
lesion
includ
vitiligo
date
approv
exvivo
treatment
cutan
tcell
lymphoma
psoralen
uva
puva
therapi
treatment
psoriasi
extracorpor
photopheresi
treatment
treat
graft
reject
syndrom
averag
dietari
uptak
natur
occur
psoralen
rang
mgday
amotosalen
develop
result
extens
studi
mani
differ
psoralen
analyz
potenti
specif
target
nucleic
acid
compat
biolog
function
platelet
plasma
compon
criteria
met
amotosalen
demonstr
excel
activ
broad
rang
pathogen
virus
bacteria
includ
spirochet
protozoa
well
leukocyt
due
high
specif
nucleic
acid
minim
interact
protein
cellular
compon
function
properti
blood
compon
preserv
amotosalen
like
psoralen
tricycl
molecul
consist
furan
pyron
moieti
introduct
amin
side
chain
render
amotosalen
highli
water
solubl
less
lipophil
thu
quickli
pass
cellular
membran
bacteri
wall
viral
envelop
readili
interact
nucleic
acid
without
interact
protein
cellular
lipid
chemic
structur
amotosalen
chang
upon
cell
entri
therefor
also
except
well
suit
inactiv
intracellular
pathogen
differ
photoact
compound
current
use
readili
intercal
doublehel
structur
dna
rna
coval
bond
reactiv
group
pyrimidin
base
form
upon
uva
illumin
even
intrastrand
reaction
possibl
thu
singlestrand
nucleic
acid
also
serv
target
chemic
interact
well
describ
highli
specif
amotosalen
commonli
use
platform
well
suit
process
well
doubledos
apheresi
collect
pool
buffi
coat
treat
singl
process
split
two
platelet
unit
transfus
technolog
allow
inactiv
platelet
plasma
differ
plateletaddit
solut
pa
intersol
ssp
pa
ce
markregist
use
intercept
system
approach
addit
solut
plasma
remov
replac
addit
solut
center
chang
product
plasma
addit
solut
benefit
gain
concurr
plasma
fraction
purpos
function
integr
intercepttr
platelet
proven
seri
vitro
assay
measur
paramet
eg
glucos
consumpt
lactat
gener
extent
shape
chang
hypoton
shock
respons
express
activ
marker
like
ph
valu
hemostat
function
intercepttr
platelet
adhes
aggreg
capac
evalu
flow
condit
ex
vivo
perfus
model
cours
storag
day
lozano
et
al
found
hemostat
function
similar
convent
platelet
storag
bag
either
storag
room
temperatur
day
platelet
freez
plasma
handson
time
prepar
pathogeninactiv
product
intercept
blood
system
less
min
especi
use
dualstorag
set
platelet
throughput
one
illumin
devic
unitsh
make
technolog
well
suit
also
larg
transfus
center
intercept
blood
system
offer
highest
degre
synergi
singl
platform
use
pathogen
inactiv
platelet
plasma
illumin
devic
activ
compound
amotosalen
similar
product
step
appli
bring
mani
advantag
instal
mainten
devic
train
personnel
prepar
sop
simplifi
addit
singl
devic
cours
save
laboratori
space
costsav
intercept
blood
system
design
broadli
compat
differ
platelet
plasma
collect
platform
intercept
platelet
process
perform
pool
whole
bloodderiv
platelet
buffi
coat
buffi
coat
approach
special
interest
term
econom
doubledos
product
produc
singl
treatment
apheresi
platelet
collect
irschlin
intercept
treatment
valu
determin
factor
viii
fibrinogen
show
largest
declin
two
well
factor
valu
well
rang
therapeut
plasma
unit
intercepttr
plasma
test
sever
clinic
trial
involv
differ
patient
group
demonstr
highli
effici
patient
congenit
acquir
coagulopathi
well
treatment
patient
requir
therapeut
plasma
exchang
moreov
intercept
plasma
product
activ
hemovigil
program
establish
show
high
level
safeti
toler
low
frequenc
acut
transfus
reaction
compar
convent
plasma
technolog
compat
pathogen
inactiv
fresh
frozen
plasma
previous
frozen
plasma
altogeth
differ
dispos
set
avail
treatment
platelet
plasma
compon
enabl
pathogen
inactiv
broad
rang
compon
volum
tabl
day
storag
total
clinic
trial
enrol
patient
conduct
demonstr
efficaci
safeti
clinic
use
intercepttr
platelet
use
routin
support
thrombocytopen
patient
whether
prophylaxi
cours
acut
bleed
number
eu
center
produc
intercept
platelet
routin
product
sever
year
provid
treatment
mani
differ
patient
group
retrospect
analysi
platelet
transfus
one
center
provid
exclus
intercept
platelet
show
increas
platelet
util
red
blood
cell
concentr
util
consist
retent
clinic
effici
compar
convent
platelet
compon
intercept
plasma
process
compat
either
apheresi
whole
bloodderiv
plasma
whole
blood
plasma
unit
mix
process
use
singl
treatment
result
three
therapeut
unit
plasma
contain
ml
sever
studi
analyz
retent
coagul
factor
inhibitor
tion
prone
develop
cancer
earli
age
therefor
exposur
potenti
carcinogen
provid
sensit
model
assess
carcinogen
studi
perform
mice
challeng
week
time
week
amount
amotosalen
human
clinic
exposur
cancer
observ
anim
also
pharmacolog
safeti
cn
cardiovascular
renal
system
furthermor
phototox
vein
irrit
assess
larg
multipl
anticip
clinic
exposur
studi
done
use
differ
anim
includ
rodent
dog
primat
addit
adm
absorpt
distribut
metabol
excret
studi
analyz
metabol
amotosalen
well
occup
safeti
studi
conduct
evalu
safeti
personnel
work
product
blood
compon
tabl
studi
amotosalen
use
concentr
repres
high
multipl
actual
clinic
exposur
specif
target
organ
toxic
reproduct
toxic
carcinogen
observ
effect
cn
electrocardiogram
detect
expect
clinic
exposur
taken
togeth
even
extens
analys
reveal
toxicolog
relev
effect
method
appli
photoreact
compound
independ
compound
natur
synthet
uv
light
lead
gener
photoproduct
regard
especi
highenergi
shortwavelength
uvb
uvc
light
disadvantag
exampl
due
gen
technolog
mechan
action
involv
direct
interact
dna
rna
whether
involv
photoact
compound
highenergi
light
critic
establish
safeti
profil
amotosalen
develop
accord
standard
intern
confer
harmon
drug
develop
addit
recommend
studi
studi
conduct
pertin
test
safeti
amotosalen
dose
intraven
studi
design
accord
assess
circumst
clinic
use
patient
perspect
therefor
broad
rang
pharmacokinet
toxicolog
analys
perform
larg
seri
studi
perform
amotosalen
alon
well
platelet
plasma
compon
treat
intercept
blood
system
without
use
cad
includ
anim
studi
acut
chronic
toxicolog
also
studi
assess
longterm
toxicolog
like
genotox
reproduct
toxicolog
neonat
juvenil
anim
develop
carcinogen
importantli
studi
reproduct
toxic
great
impact
assess
longterm
safeti
product
highest
import
decis
use
intercepttr
compon
support
pregnant
women
women
childbear
potenti
interestingli
studi
genotox
reveal
safeti
profil
amotosalen
much
higher
earlier
mention
routin
use
puva
therapi
carcinogen
analyz
appli
heterogen
knockout
model
gene
encod
tumor
suppressor
mice
respect
muta
toxicolog
studi
intercept
review
north
american
food
drug
administr
well
european
author
paul
ehrlich
institut
germani
swiss
medic
switzerland
afssap
franc
defici
toxicolog
program
identifi
patient
safeti
surviv
transfus
blood
compon
recipi
import
analyz
possibl
neoantigen
format
immun
respons
could
gener
result
interact
erat
activ
oxygen
speci
mention
earlier
intercept
technolog
per
se
offer
seri
safeti
measur
import
highli
specif
control
mechan
action
ex
vivo
treatment
process
ie
natur
activ
compound
use
longwavelength
uva
light
nm
furthermor
chemistri
amotosalennucl
acid
interact
well
understood
occur
upon
illumin
uva
light
soon
light
sourc
turn
reaction
stop
addit
safeti
measur
use
cad
shown
reduc
amount
residu
amotosalen
approxim
fig
select
process
molecul
like
protein
adsorb
cad
matrix
remov
amotosalen
free
photoproduct
add
addit
control
process
anim
studi
also
phase
phase
ii
clinic
trial
perform
healthi
volunt
shown
even
without
cad
toxic
observ
thorough
analysi
perform
analyz
potenti
safeti
risk
associ
intercept
technolog
summari
neither
toxicolog
pharmacokinet
studi
perform
amotosalen
platelet
ical
trial
enrol
addit
activ
intercept
hemovigil
program
current
perform
accumul
data
safeti
transfus
total
transfus
intercepttr
product
perform
altogeth
clinic
experi
evid
immun
respons
potenti
neoantigen
format
patient
repeatedli
expos
intercept
platelet
plasma
base
result
one
postul
exposur
intercept
blood
compon
low
probabl
immun
respons
potenti
neoantigen
sinc
discuss
earlier
technolog
appli
photoreact
substanc
light
energi
sourc
lead
photoproduct
format
best
safeguard
unwant
side
reaction
integr
adsorpt
devic
filter
remov
reaction
product
prior
transfus
patient
impress
panel
clinic
studi
enrol
patient
perform
intercepttr
platelet
plasma
compon
includ
divers
patient
group
analyz
differ
endpoint
clinic
trial
intercepttr
platelet
count
increment
ci
correct
count
increment
cci
valu
incid
acut
transfus
reaction
proport
patient
grade
bleed
assess
primari
endpoint
assess
complex
endpoint
bleed
demand
perform
accord
criteria
requir
studi
appropri
size
guarante
statist
power
sprint
studi
analyz
grade
bleed
primari
grade
bleed
one
secondari
endpoint
random
control
doubleblind
noninferior
studi
design
suffici
size
n
power
evalu
clinic
hemostasi
respons
transfus
intercept
convent
platelet
sprint
trial
demonstr
noninferior
intercepttr
platelet
grade
grade
bleed
studi
patient
diagnos
acut
myelogen
leukemia
n
acut
lymphoblast
leukemia
n
studi
transfus
convent
gammairradi
pathogeninactiv
use
intercept
blood
system
apelseth
et
al
report
platelet
dose
qualiti
platelet
import
optim
immedi
transfus
respons
wherea
durat
transfus
effect
influenc
mainli
patient
variabl
although
report
lower
ci
cci
result
intercept
treatment
correl
observ
platelet
ci
chang
clinic
bleed
statu
transfus
recent
public
kerckhoff
et
al
report
outcom
multicent
unblind
random
noninferior
trial
hovon
compar
clinic
effect
buffi
coatderiv
leukoreduc
platelet
compon
store
day
plasma
platelet
store
interphotoreact
compound
photoproduct
lipid
protein
platelet
plasma
prepar
recipi
major
caus
druginduc
immun
thrombocytopenia
result
antigen
format
drug
metabolit
platelet
surfac
glycoprotein
recent
plasma
proteom
analys
demonstr
lack
interact
amotosalen
major
platelet
surfac
glycoprotein
one
hallmark
intercept
technolog
high
degre
specif
amotosalen
dna
rna
select
bind
pyrimidin
base
vast
major
literatur
psoralen
describ
select
class
molecul
order
evalu
potenti
neoantigen
format
result
intercept
process
studi
perform
analyz
amount
amotosalen
photoproduct
step
procedur
analys
import
compound
adsorpt
devic
remov
residu
amotosalen
photoproduct
shown
analys
neoantigen
detect
photochem
treatment
platelet
plasma
sensit
immun
assay
detect
antibodi
treat
platelet
plasma
develop
surveil
clinic
studi
patient
serum
sampl
intercept
phase
iii
clinic
trial
trial
intercept
platelet
trial
intercept
plasma
analyz
presenc
antibodi
potenti
amotosalen
neoantigen
larg
doubleblind
random
control
trial
enrol
hematooncolog
patient
need
multipl
platelet
transfus
design
patient
continu
recurr
thrombocytopenia
subgroup
enrol
patient
elig
secondari
period
platelet
transfus
allow
evalu
immun
respons
multipl
transfus
intercept
platelet
period
time
time
two
treatment
cycl
would
optim
antibodi
format
occur
furthermor
sprint
trial
incid
lymphocytotox
antibodi
low
statist
less
intercept
group
compar
convent
group
plateletspecif
antibodi
found
refractori
patient
receiv
intercept
platelet
patient
receiv
convent
platelet
summari
patient
sampl
taken
clinic
trial
show
none
patient
exhibit
clinic
laboratori
manifest
neoantigen
beyond
alter
platelet
membran
protein
identifi
base
test
lymphocytotox
antibodi
plateletspecif
alloantibodi
addit
independ
expert
analysi
sprint
trial
patient
data
reveal
evid
increas
incid
lunginjuri
ali
transfus
intercept
treat
platelet
compar
convent
platelet
patient
receiv
intercepttr
product
cours
clindonor
climat
chang
allow
vector
given
pathogen
surviv
countri
condit
chang
favor
describ
mechan
action
intercept
technolog
especi
fact
interact
amotosalen
dna
rna
molecul
sequencespecif
theoret
allow
inactiv
nearli
even
yet
unknown
pathogen
spectrum
includ
envelop
virus
like
inactiv
capac
demonstr
intracellular
well
cellfre
virus
addit
hiv
viru
isol
patient
suffer
hiv
infect
cellassoci
virus
like
htlv
cmv
inactiv
high
degre
inactiv
result
latter
suffici
support
center
perform
intercept
treatment
platelet
could
replac
cmv
serolog
accord
respect
nation
regulatori
author
cours
major
impact
inventori
manag
cost
save
due
decreas
expiri
rate
platelet
compon
center
manag
dual
inventori
reli
cmv
serolog
maintain
cmvneg
donor
save
may
signific
center
issu
leukoreduc
blood
compon
cmvneg
indic
inactiv
intracellular
virus
becom
import
featur
technolog
xmrvmlv
recent
detect
tissu
patient
suffer
prostat
carcinoma
blood
patient
chronic
fatigu
syndrom
appar
xmrvmlv
among
cell
type
seem
use
also
lymphocyt
replic
recent
inactiv
xmrvmlv
intercept
blood
system
demonstr
platelet
erythrocyt
compon
also
hepat
virus
includ
hbv
hcv
inactiv
effect
broad
spectrum
envelop
virus
effici
inactiv
demonstr
also
includ
duck
hepat
b
viru
bovin
viral
diarrhea
viru
pseudorabiesviru
vaccinia
viru
influenza
strain
studi
perform
infect
studi
cell
cultur
anim
model
effici
nonenvelop
virus
inactiv
vari
strongli
differ
virus
adenoviru
bluetongu
viru
suscept
treatment
parvoviru
intermedi
level
inactiv
could
demonstr
tabl
hav
caliciviru
low
degre
suscept
inactiv
great
interest
capac
intercept
technolog
inactiv
emerg
reemerg
pathogen
highli
effect
inactiv
demonstr
exampl
larg
panel
emerg
virus
includ
coronaviru
caus
sar
west
nile
viru
earlier
mention
influenza
strain
well
chickungunya
viru
dengu
viru
versatil
effici
intercept
blood
system
demonsol
without
intercept
treatment
patient
studi
power
platelet
ci
cci
result
somewhat
compar
previous
report
find
transfus
intercepttr
platelet
result
lower
ci
cci
respons
patient
import
mention
though
hovon
studi
intercepttr
platelet
addit
gammairradi
high
percentag
treatment
requir
intercept
platelet
caus
unneed
damag
platelet
thu
caus
lower
ci
cci
valu
interest
also
result
tessi
studi
efficaci
intercepttr
platelet
store
day
analyz
multicent
random
control
doubleblind
studi
met
primari
endpoint
cci
valu
thu
demonstr
noninferior
intercept
platelet
compar
convent
platelet
despit
hovon
studi
underpow
bleed
assess
author
also
report
observ
bleed
event
intercept
arm
therefor
conclud
intercepttr
platelet
inferior
untreat
platelet
store
plasma
conclus
illustr
challeng
conduct
platelet
transfus
clinic
trial
exampl
imbal
patient
random
high
rate
offprotocol
transfus
hovon
make
definit
conclus
question
addit
recent
platelet
dose
studi
plado
patient
power
bleed
assess
patient
studi
arm
clearli
show
low
dose
platelet
transfus
associ
bleed
taken
togeth
power
assess
hemostasi
requir
studi
significantli
larger
size
hovon
studi
defin
per
protocol
method
conduct
observ
blind
treatment
insur
adequ
classif
bleed
differ
method
assess
bleed
lack
blind
high
degre
offprotocol
transfus
inadequ
studi
size
hovon
studi
like
contribut
discrep
report
bleed
compar
plado
sprint
studi
experi
hemovigil
program
routin
use
intercept
platelet
pathogen
inactiv
pathogen
reduct
technolog
versatil
test
broad
panel
pathogen
possibl
date
major
threat
transfusiontransmit
diseas
bacteria
grow
platelet
product
due
storag
room
temperatur
addit
emerg
reemerg
pathogen
great
concern
transfus
platelet
plasma
compon
mostli
result
worldwid
travel
immigr
tabl
pathogeninactiv
platelet
concentr
retain
day
growth
bacteria
upon
cultiv
analyz
even
hold
period
bacteri
growth
could
detect
intercepttr
product
bacteri
spore
like
bacillu
cereu
quit
resist
pathogen
inactiv
veget
form
b
cereu
instead
suscept
intercept
treatment
import
mention
bacteria
like
b
cereu
normal
exist
veget
form
blood
form
spore
mechan
surviv
condit
favor
regard
spore
might
real
import
threat
transfus
blood
compon
recent
studi
compar
capac
bacteri
detect
method
intercept
technolog
reduc
risk
associ
transfus
platelet
compon
contamin
low
level
bacteria
author
conclud
bacteri
detect
method
could
lead
contamin
product
releas
transfus
base
testneg
result
inactiv
could
reduc
risk
recent
year
number
report
concern
infect
emerg
protozoa
increas
biggest
concern
plasmodium
falciparum
malaria
trypanosoma
cruzi
chaga
diseas
leishmania
babesia
microti
abil
strate
chickungunya
epidem
occur
french
oversea
depart
ile
de
la
reunion
one
third
popul
infect
viru
local
blood
suspend
due
fact
intercept
technolog
approv
french
regulatori
bodi
afssap
intercept
technolog
platelet
rapidli
implement
implement
intercept
blood
system
case
chickungunya
transmiss
via
blood
compon
report
similar
experi
occur
guadeloup
la
martiniqu
recent
dengu
outbreak
caus
sever
problem
also
intercept
technolog
help
provid
safe
platelet
compon
besid
emerg
pathogen
bacteria
major
threat
blood
safeti
especi
platelet
compon
therefor
technolog
pathogen
inactiv
achiev
highest
level
inactiv
test
capac
intercept
technolog
inactiv
bacteria
studi
broad
spectrum
aerob
anaerob
gramposit
gramneg
bacteria
well
spirochet
perform
assay
shown
slowgrow
fastgrow
bacteria
well
sampl
contain
low
titer
high
titer
bacteria
effect
inactiv
refer
inactiv
limit
detect
assay
case
assay
small
dynam
rang
due
limit
attain
viru
titer
inher
lowlevel
background
noninfect
indic
cell
preclud
htlv
intracellular
inactiv
also
protozoa
intercept
technolog
demonstr
recent
tabl
besid
infecti
pathogen
residu
leukocyt
caus
sever
harm
recipi
blood
compon
leukocyt
caus
transfusionassoci
graftversushost
diseas
tagvhd
especi
immunosuppress
patient
current
blood
compon
patient
risk
tagvhd
gammairradi
prevent
highli
morbid
complic
furthermor
leukocyt
caus
febril
nonhemolyt
transfus
reaction
result
cytokinechemokin
product
repres
reservoir
intracellular
pathogen
like
exampl
hiv
ebv
cmv
newli
describ
xmrvmlv
also
leishmania
although
wide
implement
leukofiltr
remov
residu
leukocyt
blood
compon
seri
experi
perform
analyz
inactiv
leukocyt
intercept
technolog
tabl
vitro
vivo
studi
mous
well
human
cell
show
inactiv
capac
exceed
gammairradi
robust
leukocyt
inactiv
intercept
demonstr
limit
dilut
assay
clonal
tcell
prolifer
comparison
gammairradi
cgi
term
degre
inactiv
technolog
compar
small
deviat
dose
gammairradi
could
caus
inactiv
fail
wherea
intercept
treatment
robust
regard
thu
exhibit
higher
safeti
margin
refer
inactiv
limit
detect
assay
intracellular
class
iib
ce
mark
requir
thorough
preclin
clinic
develop
program
also
statement
regard
perform
product
approv
offici
label
claim
therefor
anoth
differ
class
iib
product
selfdeclar
made
claim
test
base
data
submit
respect
claim
grant
intercept
blood
system
platelet
gain
ce
mark
plasma
allow
market
distribut
europ
compon
addit
intercept
blood
system
platelet
plasma
approv
french
regulatori
author
afssap
germani
paul
ehrlich
institut
grant
market
author
center
platelet
respect
file
intercept
plasma
final
stage
review
switzerland
swissmed
approv
intercept
platelet
plasma
offici
label
claim
state
intercept
treat
platelet
plasma
compon
clinic
differ
convent
compon
infus
accord
standard
clinic
practic
guidelin
patient
exclus
thu
product
use
patient
includ
neonat
children
pregnant
women
patient
undergo
stem
cell
transplant
patient
strong
chemotherapeut
treatment
ce
mark
intercepttr
platelet
offici
allow
storag
day
region
regul
appli
platelet
store
day
routin
use
sever
countri
except
franc
germani
approv
paul
ehrlich
institut
allow
use
intercept
altern
gammairradi
omit
cmv
serolog
addit
region
leukodeplet
mandatori
intercept
also
offici
perform
without
prior
leukodeplet
claim
regard
efficaci
intercept
technolog
regard
inactiv
given
pathogen
offici
grant
regulatori
author
result
selfdeclar
hei
et
al
demonstr
effect
intercept
treatment
cytokinechemokin
product
residu
leukocyt
platelet
storag
analyz
presenc
supernat
elisa
period
day
respect
gammairradi
caus
infrequ
strand
break
leukocyt
dna
express
could
detect
substanc
could
detect
intercept
treatment
similar
find
describ
cognass
et
al
demonstr
intercept
treatment
platelet
increas
releas
platelet
deriv
growth
factorab
tumor
necrosi
factor
interestingli
solubl
ligand
describ
implic
transfusionassoci
lung
injuri
result
regard
inactiv
leukocyt
led
offici
label
claim
intercept
treatment
platelet
may
replac
gammairradi
measur
prevent
tagvhd
multipl
center
differ
european
countri
stop
gammairradi
altogeth
implement
intercept
blood
system
treat
patient
risk
tagvhd
nongammairradi
intercepttr
platelet
concentr
greater
level
inactiv
pathogen
like
bacteria
virus
protozoa
spirochet
greater
contribut
technolog
safeti
blood
compon
lower
risk
patient
addit
technolog
proven
high
degre
inac
tivationreduct
pathogen
eventu
allow
chang
paradigm
blood
safeti
develop
implement
novel
screen
method
donor
deferr
proactiv
approach
name
pathogen
inactiv
intercept
technolog
provid
high
level
pathogen
inactiv
broad
spectrum
pathogen
valu
given
tabl
basi
offici
label
claim
grant
intercept
blood
system
regulatori
bodi
intercept
blood
system
regist
class
iii
ce
mark
drug
devic
combin
contrast
